News

Offering a new treatment option for psoriasis patients, Cosentyx is the first approved human monoclonal antibody (mAb) that selectively binds to interleukin IL-17A and inhibit interaction with the

The Phase II clinical trial is currently underway in nine countries, and will involve around 50 sites. Primary objective of the trial is to determine the most effective

"We have tested over 1,500 chemotherapeutic agents in our head and neck cancer cell lines and COTI-2 is the most active drug that we have ever seen in

Extended periods of stable disease were also noted in some patients with pancreatic and gastric cancers, with time-to-progression (TTP) exceeding that of last prior therapy in many cases.

This label update provides physicians with important information on the clinical utility of rivaroxaban in patients with AF who require cardioversion and is based on the positive CHMP

The AbbVie Innovation Center plans to employ more than 18 students, from undergraduate to graduate level, on a part-time basis throughout the year. Eight students have started working

The trial supports the company’s larger clinical program of CVC in non-alcoholic steatohepatitis (NASH), a disease associated with multiple comorbidities, including diabetes. The company said that pioglitazone is

Currently, VS-5584 is being evaluated in a Phase I clinical trial in patients with advanced solid tumors and a Phase I combination trial with VS-6063 (defactinib) in patients

The open-label, dose-escalating Phase I/II trial is designed to evaluate the safety and preliminary efficacy of sub-retinal administration of SPK-CHM. Spark co-founder and chief executive officer Jeffrey Marrazzo